
Product Data Sheet

Product Name: Ensitrelvir fumarate

Cat. No.: GC64368

Chemical Properties

Cas. No. 2757470-18-9

Formula C₂₆H₂₁ClF₃N₉O₆

M.Wt

647.95

Solubility

Storage

Store at -20°C

General tips

For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

Ensitrelvir is an orally bioavailable inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M^{Pro}), also known as 3C-like protease (3CL^{Pro}), with an IC₅₀ value of 0.013 μM.¹ It is selective for M^{Pro} over HIV-1 protease and the human proteases caspase-2, chymotrypsin, thrombin, and cathepsin B, -D, -G, and -L (IC₅₀s = >100 μM for all). Ensitrelvir reduces the cytopathic effects of SARS-CoV-2 clinical isolates, including Alpha, Beta, Gamma, Delta, and Omicron strains, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV), in Vero E6 cells expressing human transmembrane serine protease 2 (TMPRSS2; EC₅₀s = 0.29-1.4 μM). Oral administration of ensitrelvir decreases lung viral titers in a mouse model of SARS-CoV-2 Gamma variant infection when administered at doses ranging from 2 to 32 mg/kg at the time of, and 12 hours after, infection.

1. Unoh, Y., Uehara, S., Nakahara, K., et al. Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. *Med. Chem.* 65(9)6499-6512(2022)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA